Drotaverine in Dysmenorrhoea Treatment
This study has been terminated.
(early termination due to loss of interest and low enrollment of patient)
Information provided by:
First received: February 15, 2006
Last updated: November 14, 2008
Last verified: November 2008
The aim of the study is to show that the combination of drotaverine 80mg and ibuprofen 400 mg is more effective and as well-tolerated as ibuprofen 400 mg or drotaverine 80 mg administered alone, in the treatment of primary and secondary dysmenorrhoea.
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
||Comparison of the Efficacy and Tolerability of Drotaverine 80 mg, Ibuprofen 400 mg and Their Combination in a Calendar Packaging for the Treatment of Primary and Secondary Dysmenorrhoea
Primary Outcome Measures:
- Reponse rate in each treatment arm: proportion of patients having pain intensity score 0 or 1 at hour 2 after the first drug intake.
| Estimated Enrollment:
| Study Start Date:
|Ages Eligible for Study:
||18 Years to 45 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- History of at least 6 months of dysmenorrhea, with presence of moderate to severe pain in each of the last 3 cycles
- With regular menstrual cycles (25-35 days)
- Using an adequate barrier contraception method (except for virgins)
- Evidence of clinically relevant gynecological, cardiovascular, hematologic, hepatic, gastrointestinal, renal, pulmonary, endocrinologic, neurologic or psychiatric disease, based on a clinical assessment and routine laboratory investigations
- Proven hypersensitivity to drotaverine hydrochloride or ibuprofen or proven intolerance to lactose
- Any described contraindication to either drotaverine hydrochloride or ibuprofen (see Summary of Product Characteristics)
- Oestro-progestative contraception within the last 2 months
- Regular use of sedative, hypnotics, tranquillizers or any other addictive agents
- History or evidence of acute or chronic alcohol abuse
- Heavy smoking (> 10 cigarettes/day)
- Need of a permanent treatment with other antispasmodics and/or analgesic agents during the trial
- Participation in another clinical trial in the last 3 months prior to the start of this study
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00292747
|Budapest, Hungary |
||László Erős, MD
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||February 15, 2006
||November 14, 2008
||Hungary: National Institute of Pharmacy
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 21, 2015
Signs and Symptoms
Central Nervous System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Sensory System Agents